R
Roy S. Herbst
Researcher at University of Texas Health Science Center at Houston
Publications - 59
Citations - 8426
Roy S. Herbst is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Lung cancer. The author has an hindex of 30, co-authored 59 publications receiving 7979 citations. Previous affiliations of Roy S. Herbst include Memorial Sloan Kettering Cancer Center & Fox Chase Cancer Center.
Papers
More filters
Journal ArticleDOI
Molecular origins of cancer: Lung cancer
TL;DR: From the Departments of Thoracic/Head and Neck Medical Oncology and Clinical Cancer Prevention, University of Texas M.D. Anderson Cancer Center, Houston.
Journal ArticleDOI
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
David H. Johnson,Louis Fehrenbacher,William Novotny,Roy S. Herbst,John Nemunaitis,David M. Jablons,Corey J. Langer,Russell F. DeVore,Jacques Gaudreault,Lisa A. Damico,Eric Holmgren,Fairooz F. Kabbinavar +11 more
TL;DR: Bvacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer.
Journal ArticleDOI
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
David A. Eberhard,Bruce E. Johnson,Lukas C. Amler,Audrey Goddard,Sherry Heldens,Roy S. Herbst,William L. Ince,Pasi A. Jänne,Thomas Januario,David H. Johnson,Pam Klein,Vincent A. Miller,Michael A. Ostland,D. Ramies,Dragan Sebisanovic,Jeremy Stinson,Yu R. Zhang,Somasekar Seshagiri,Kenneth J. Hillan +18 more
TL;DR: EGFR mutations may be a positive prognostic factor for survival in advanced NSCLC patients treated with chemotherapy with or without erlotinib, and may predict greater likelihood of response.
Journal ArticleDOI
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle,Lauren Averett Byers,Edward S. Kim,Pierre Saintigny,J. Jack Lee,George R. Blumenschein,Anne Tsao,Suyu Liu,Jill E. Larsen,Jing Wang,Lixia Diao,Kevin R. Coombes,Lu Chen,Shuxing Zhang,Mena Abdelmelek,Ximing Tang,Vassiliki A. Papadimitrakopoulou,John D. Minna,Scott M. Lippman,Waun Ki Hong,Roy S. Herbst,Ignacio I. Wistuba,John V. Heymach,Garth Powis +23 more
TL;DR: Molecular modeling studies showed that different conformations imposed by mutant KRas may lead to altered association with downstream signaling transducers, and implies that therapeutic interventions may need to take into account the specific mutants expressed by the tumor.
Journal ArticleDOI
Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
Vincent A. Miller,Gregory J. Riely,Maureen F. Zakowski,Allan R. Li,Jyoti D. Patel,Robert T. Heelan,Mark G. Kris,Alan Sandler,D. P. Carbone,Anne Tsao,Roy S. Herbst,Glenn Heller,Marc Ladanyi,William Pao,David H. Johnson +14 more
TL;DR: Testing for EGFR and KRAS mutations can predict RR and PFS after treatment with erlotinib in this histologically enriched subset of patients with non-small-cell lung cancer (NSCLC) and are suggested to be reported in clinical trials in NSCLC using EGFR-directed therapy.